Novo Nordisk

Pharmaceuticals · NVO

Maker of semaglutide (Wegovy, Ozempic). Its GLP-1 franchise is the cost line employers are rationing, and the market Ilant is built around.

Market snapshot

NYSE: NVO

41.71USD▼ 1.93%−0.82 today

Open · delayed 15 min · Sep 16 4:37 PM EDT

Open: 42.47
Mkt cap: 184.31B
High: 42.72
Low: 41.47
52-wk high: 64.16
Dividend: 2.78%
52-wk low: 35.12
Qtrly div amt: 0.58

Day figures as of Sep 16 4:41 PM EDT · previous close 42.53

Latest on Novo Nordisk

1 story

Featured · Health

This AI startup raised $15 million amid employer cuts to weight-loss drug coverage, but its proof is shaky.

Ilant Health pitches obesity care to employers. Its headline result sets its one-year 15% weight loss against a drug-free program's five-year 5.8%. At one year, that same program reported 12.4%.

September 10, 2026 · 3 min read